Technical Analysis for CCXI - ChemoCentryx, Inc.

Grade Last Price % Change Price Change
F 12.76 -1.01% -0.13
CCXI closed down 1.01 percent on Wednesday, June 23, 2021, on 79 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical CCXI trend table...

Date Alert Name Type % Chg
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Narrow Range Bar Range Contraction -1.01%
NR7 Range Contraction -1.01%
Inside Day Range Contraction -1.01%
Wide Bands Range Expansion -1.01%
Down 3 Days in a Row Weakness -1.01%
Stochastic Sell Signal Bearish -2.30%
Older End-of-Day Signals for CCXI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 18 hours ago
Outside Day about 18 hours ago
Down 3% about 18 hours ago
Down 2 % about 18 hours ago
Fell Below Previous Day's Low about 18 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


ChemoCentryx, Inc. Description

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trials for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 that is in Phase II clinical trials for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company's drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis, an inflammatory disease; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for chronic hepatitis. ChemoCentryx, Inc. has a strategic alliance with Glaxo Group Limited for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets and for advancing them through clinical proof-of-concept. The company was founded in 1997 and is headquartered in Mountain View, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Clinical Development Autoimmune Diseases Monoclonal Antibodies Autoimmune Disease Inflammatory Disease Rheumatoid Arthritis Kidney Disease Blastoma Inflammatory Bowel Disease Glioblastoma Dermatitis Renal Disease Atopic Dermatitis Diabetic Nephropathy Immunosuppressants Related Disorders Inflammatory Disorders Biotie Therapies Glioblastoma Multiforme Chronic Hepatitis Janus Kinase Inhibitor Vasculitis

Is CCXI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Jun 24 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ChemoCentryx, AcelRx, Ocugen, and Tarena and Encourages Investors to Contact the Firm
Jun 23 CLASS ACTION UPDATE for CCXI, ATER and RLX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Jun 23 Rosen, A Leading Law Firm, Encourages ChemoCentryx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 6 Deadline in Securities Class Action - CCXI
Jun 23 Investor Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc. (CCXI)
Jun 23 FINAL DEADLINE APPROACHING: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Jun 23 SHAREHOLDER ALERT: CCXI RLX HMPT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Jun 23 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ChemoCentryx (CCXI) Investors with Losses to Contact the Firm Now, Securities Fraud Deadline Approaching
Jun 23 UPCOMING DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Jun 23 Is ChemoCentryx a Buy?
Jun 22 The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CCXI, PRVB and WPG
See more CCXI news...


Indicator Value
52 Week High 70.22
52 Week Low 9.53
Average Volume 4,078,114
200-Day Moving Average 48.50
50-Day Moving Average 21.94
20-Day Moving Average 11.61
10-Day Moving Average 12.87
Average True Range 1.27
ADX 39.25
+DI 20.19
-DI 30.00
Chandelier Exit (Long, 3 ATRs) 10.43
Chandelier Exit (Short, 3 ATRs) 13.33
Upper Bollinger Bands 14.33
Lower Bollinger Band 8.90
Percent B (%b) 0.71
BandWidth 46.76
MACD Line -1.78
MACD Signal Line -2.89
MACD Histogram 1.115
Fundamentals Value
Market Cap 883.1 Million
Num Shares 69.2 Million
EPS -0.92
Price-to-Earnings (P/E) Ratio -13.82
Price-to-Sales 50.29
Price-to-Book 9.54
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.31
Resistance 3 (R3) 14.28 13.73 14.05
Resistance 2 (R2) 13.73 13.34 13.75 13.96
Resistance 1 (R1) 13.25 13.10 12.98 13.28 13.88
Pivot Point 12.70 12.70 12.57 12.72 12.70
Support 1 (S1) 12.22 12.31 11.95 12.25 11.64
Support 2 (S2) 11.67 12.07 11.69 11.56
Support 3 (S3) 11.19 11.67 11.47
Support 4 (S4) 11.22